Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals Co., Ltd., has received conditional approval from the National Medical Products Administration for its self-developed Class 1 innovative drug, Famitinib Malate Capsules. This drug, to be used in combination with Camrelizumab for Injection, is indicated for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment. This approval marks a significant milestone for the company, enhancing its position in the oncology market and potentially expanding its market share in innovative cancer therapies.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading pharmaceutical company in China, specializing in the development and production of innovative drugs. The company focuses on oncology, anesthesiology, and cardiovascular treatments, aiming to provide advanced therapeutic solutions in these areas.
Average Trading Volume: 27,396,529
Current Market Cap: HK$369.6B
For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.